EP Patent

EP1766010A1 — Antisense oligonucleotides for inducing exon skipping and methods of use thereof

Assigned to University of Western Australia · Expires 2007-03-28 · 19y expired

What this patent protects

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

USPTO Abstract

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

Drugs covered by this patent

Patent Metadata

Patent number
EP1766010A1
Jurisdiction
EP
Classification
—
Expires
2007-03-28
Drug substance claim
No
Drug product claim
No
Assignee
University of Western Australia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.